Sec Form 13D Filing - Fortress Biotech Inc. (FBIO) filing for AVENUE THERAPEUTICS INC. (ATXI) - 2024-04-17

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13D

(Amendment No. 4)

 

Under the Securities Exchange Act of 1934

 

 

AVENUE THERAPEUTICS, INC.

(Name of Issuer)

 

 

Common Stock, $0.0001 Par Value

(Title of Class of Securities)

 

05360L304

(CUSIP Number)

 

Fortress Biotech, Inc. c/o Lindsay A. Rosenwald, M.D. 1111 Kane Concourse, Suite 301 Bay Harbor Islands, FL 33154 (781) 652-4500

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

 

April 16, 2024

(Date of Event which Requires Filing of this Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

 

 

*	The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 05360L304

Page 2 of 7

 

1.	Name of Reporting Person
	I.R.S. Identification No. of Above Person (Entities Only)
	Fortress Biotech, Inc. 20-5157386
2.	Check the Appropriate Box if a Member of a Group
	Not Applicable
	(a) ¨
	(b) ¨
3.	SEC Use Only
4.	Source of Funds (See Instructions)
	OO
5.	Check if Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e)
	Not Applicable

 

6.	Citizenship or Place of Organization
	Delaware

	7.	Sole Voting Power
Number of		3,564,0591
Shares
Beneficially	8.	Shared Voting Power
Owned By
Each Reporting		0
Person with
	9.	Sole Dispositive Power
		3,541,8372
	10.	Shared Dispositive Power
		22,2223

11.	Aggregate Amount Beneficially Owned by Each Reporting Person
	3,564,0591

 

12.	Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares
	¨
13.	Percent of Class Represented by Amount in Row (11)
	8.0% of all outstanding shares of Issuer common stock4
14.	Type of Reporting Person
	HC, CO

 

 

CUSIP No. 05360L304

Page 3 of 7

 

1

Includes 22,222 shares of Issuer’s common stock underlying Warrants and 250,000 shares of the Issuer’s Class A preferred stock (both of which are described further below). The Issuer’s Class A preferred stock is identical to its common stock other than as to voting rights, conversion rights and the PIK Dividend (as defined below) rights. Each share of the Issuer’s Class A preferred stock is entitled to the number of votes per share that is equal to one and one-tenth (1.1) times a fraction, the numerator of which is the sum of (A) the number of shares of the Issuer’s outstanding common stock and (B) the whole number of shares of the Issuer’s common stock into which any shares of outstanding Class A preferred stock are convertible and the denominator of which is the number of shares of outstanding Class A preferred stock. All shares of the Class A preferred stock are convertible into 16,666 shares of the Issuer’s common stock. Thus, the Class A preferred stock will at all times constitute a voting majority. The Reporting Person owns all outstanding shares of the Issuer’s Class A preferred stock. As holders of Class A preferred stock, the Reporting Person will receive on each January 1 (each a “PIK Dividend Payment Date”) until the date all outstanding Class A preferred stock is converted into common stock or redeemed (and the purchase price is paid in full), pro rata per share dividends paid in additional fully paid and nonassessable shares of Issuer common stock (“PIK Dividends”) such that the aggregate number of shares of common stock issued pursuant to such PIK Dividend is equal to two and one-half percent (2.5%) of the Issuer’s fully-diluted outstanding capitalization on the date that is one (1) business day prior to any PIK Dividend Payment Date. An aggregate 22,222 shares of Issuer common stock are issuable under Common Stock Warrants dated July 15, 2012, as amended by the Amended and Restated Common Stock Warrant dated December 12, 2016, issued by the Reporting Person to Lindsay A. Rosenwald, M.D., the Reporting Person’s Chairman, President and Chief Executive Officer and Michael S. Weiss, the Reporting Person’s Executive Vice Chairman, Strategic Development, pursuant to the Fortress Biotech, Inc. Long-Term Incentive Plan (the “Warrants”). The Warrants, which have an exercise price of $6.57 per share, are exercisable until July 15, 2035. The Reporting Person must reserve from its holdings of the Issuer’s common stock the shares underlying the Warrants until the Warrants are exercised. The foregoing description of the Warrants is not complete and is qualified in its entirety by reference to the full text of the form of the Amended and Restated Common Stock Warrant which is attached as Exhibit 7.01 and incorporated herein by reference. Mr. Weiss served as a member of the Issuer’s Board of Directors from March 2015 until February 8, 2019, and has served as a director and Executive Vice Chairman of the Reporting Person since February 2014. Dr. Rosenwald has served as a member of the Issuer’s Board of Directors since 2015 and has been a member of the Board of Directors of the Reporting Person since October 2009 and has served as its Chairman, President and Chief Executive Officer since December 2013.

 

2	Excludes the 22,222 shares of Issuer’s common stock underlying the Warrants.

 

3	Consists solely of the 22,222 shares of Issuer’s common stock underlying the Warrants.

 

4

Includes 22,222 shares of Issuer’s common stock underlying Warrants described above and 250,000 shares of the Issuer’s Class A preferred stock, convertible into 16,666 shares of the Issuer’s common stock. Percentage based upon 44,260,667 shares of the Issuer’s common stock as of March 1, 2024 as reported by the Issuer on its Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 18, 2024, and the assumed conversion of the Class A preferred stock.

 

 

CUSIP No. 05360L304

Page 4 of 7

 

Explanatory Note:  

 

This Amendment No. 4 (the “Amendment No. 4”) amends and supplements the statement on Schedule 13D, Amendment No. 1, Amendment No. 2, and Amendment No. 3 to such Schedule 13D filed respectively on October 19, 2017, April 19, 2019, January 6, 2023, and September 18, 2023 (collectively, the “Schedule 13D”) with the U.S. Securities and Exchange Commission relating to the Common Stock of Avenue Therapeutics, Inc. (the “Issuer”), by Fortress Biotech, Inc. (the “Reporting Person”). Except as specifically provided herein, this Amendment No. 4 does not modify any of the information previously reported on the Schedule 13D. Capitalized terms used but not defined herein shall have the same meanings as are ascribed to them in the Schedule 13D, as applicable. 

 

Item 1.

Security and Issuer

 

This amendment to a statement on Schedule 13D relates to the common stock of the Issuer. The Issuer’s principal executive office is located at 1111 Kane Concourse, Suite 301, Bay Harbor Islands, Florida 33154.

 

Item 2.

Identity and Background

 

(a)

This Schedule 13D/A is being filed on behalf of the Reporting Person pursuant to Rule 13d-1 of Regulation D-G under the Act.

 

(b)

The address of the Reporting Person's principal business and principal office is 1111 Kane Concourse, Suite 301, Bay Harbor Islands, Florida 33154.

 

(c)

The principal business of the Reporting Person is acquiring, developing and commercializing novel pharmaceutical and biotechnology products both within the Reporting Person and through certain of its subsidiary companies.

 

(d) – (e)

During the last five years, the Reporting Person: (i) has not been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors); and (ii) has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction resulting in it being subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

 

(f)

The Reporting Person is organized under the laws of the state of Delaware.

 

Item 3.

Source and Amount of Funds or Other Consideration.

 

The Reporting Person is filing this Schedule 13D Amendment as a result of the acquisition of 413,507 shares of the Issuer’s common stock related to an Offering Equity Grant (as defined below) resulting from a transaction completed in the first fiscal quarter of 2024. The Issuer made the Offering Equity Grant pursuant to the terms of the Founders Agreement, entered into by the Reporting Person and the Issuer and amended and restated on September 13, 2016 (as amended, the “Founders Agreement”). The Founders Agreement provides that, in exchange for the time and capital expended by the Reporting Person in the formation of the Issuer and the identification of specific assets, the acquisition of which was anticipated to result in the formation of a viable emerging growth life science company, the Issuer (i) will issue annually to the Reporting Person, on January 1 of each calendar year, shares of Issuer common stock equal to two and one-half percent (2.5%) of the fully-diluted outstanding equity of the Issuer at the time of issuance (an “Annual Equity Grant”); and (ii) will pay an equity fee in shares of Issuer common stock equal to two and one-half percent (2.5%) of the gross amount of any equity or debt financing transaction of the Issuer or any of its respective subsidiaries that occurs after the effective date of the original Founders Agreement and ending on the date when the Reporting Person no longer has majority voting control of the Issuer’s voting equity (an “Offering Equity Grant”).

 

 

CUSIP No. 05360L304

Page 5 of 7

 

Item 4.

Purpose of Transaction.

 

The Reporting Person acquired 413,507 shares of the Issuer’s common stock as an Offering Equity Grant resulting from a transaction completed by the Issuer in the first fiscal quarter of 2024. The Reporting Person does not have any present plans or proposals that relate to or would result in: (i) the acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer, except for: (a) 22,222 shares underlying the Warrants described in Footnote 1; (b) any additional PIK Dividends that may be made pursuant to the Class A Preferred Stock as further described in Footnote 1; and (c) any shares of the Issuer’s common stock it may receive as a result of future Offering Equity Grants; (ii) an extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of the Issuer’s subsidiaries; (iii) a sale or transfer of a material amount of assets of the Issuer or any of the Issuer’s subsidiaries; (iv) any change in the present board of directors or management of the Issuer; (v) any material change in the present capitalization or dividend policy of the Issuer; (vi) any other material change in the Issuer’s business or corporate structure; (vii) changes in the Issuer’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; (viii) causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; (ix) a class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934; or (x) any action similar to any of those enumerated above.

 

Item 5.

Interest in Securities of the Issuer.

 

(a) – (c) The Reporting Person is the beneficial owner of 3,564,059 shares of the Issuer’s common stock (including 250,000 shares of the Issuer’s Class A preferred stock, which are convertible into 16,666 shares of the Issuer’s common stock). The Reporting Person’s shares of the Issuer’s common stock represent beneficial ownership of approximately 8.0% of the Issuer’s outstanding common stock, based upon 44,260,667 outstanding shares of the Issuer’s common stock as reported by the Issuer on its Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 18, 2024, and the assumed conversion of the Class A preferred stock.

 

(d) Except with respect to the Warrants described in Footnote 1, no person has the power to direct the receipt of dividends on or the proceeds of sales of, the shares of common stock owned by the Reporting Person.

 

(e) Not Applicable.

 

 

CUSIP No. 05360L304

Page 6 of 7

 

Item 6.	Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
	Reference is made to the Warrants in Footnote 1 above.

 

Item 7.

Materials to be Filed as Exhibits.

 

	Exhibit 7.01	Second Amended and Restated Certificate of Incorporation of Avenue Therapeutics, Inc., dated September 12, 2016, incorporated by reference to Exhibit 3.1 to the  Form 10-12G filed by the Issuer with the SEC on January 12, 2017 (File No. 000-55556).*
	Exhibit 7.02	Form of Common Stock Warrant filed as Exhibit 4.2 to Form 10-12G filed by the Issuer with the SEC on January 12, 2017 (File No. 000-55556) and incorporated herein by reference.*
	Exhibit 7.03	Amended and Restated Founders Agreement between Fortress Biotech, Inc. and Avenue Therapeutics, Inc., dated September 13, 2016, incorporated by reference to Exhibit 10.2 to the Form 10-12G filed by the Issuer with the SEC on January 12, 2017 (File No. 000-55556).*

 

*	Previously Filed.

 

 

CUSIP No. 05360L304

Page 7 of 7

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

< /tr>

Date: April 17, 2024
	FORTRESS BIOTECH, INC.
	By:	/s/ Lindsay A. Rosenwald
	Name:	Lindsay A. Rosenwald, M.D.
	Title:	Chairman, President and Chief Executive Officer